Quantbot Technologies LP Biocryst Pharmaceuticals Inc Transaction History

Quantbot Technologies LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$4.89 - $7.65 $97,311 - $152,235	19,900 Added 829.17%	22,300 $113,000
Q4 2023 Feb 14, 2024	SELL	$4.98 - $6.77 $307,266 - $417,709	-61,700 Reduced 96.26%	2,400 $14,000
Q3 2023 Nov 07, 2023	BUY	$6.71 - $7.92 $430,111 - $507,672	64,100 New	64,100 $453,000
Q1 2023 May 12, 2023	BUY	$7.94 - $11.84 $131,010 - $195,360	16,500 New	16,500 $137,000
Q4 2021 Feb 11, 2022	SELL	$11.18 - $15.46 $556,764 - $769,908	-49,800 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$14.21 - $17.65 $677,817 - $841,904	47,700 Added 2271.43%	49,800 $715,000
Q2 2021 Aug 12, 2021	SELL	$9.5 - $17.24 $131,100 - $237,911	-13,800 Reduced 86.79%	2,100 $33,000
Q1 2021 May 14, 2021	BUY	$7.37 - $13.61 $117,183 - $216,399	15,900 New	15,900 $161,000
Q4 2020 Feb 12, 2021	SELL	$3.37 - $8.61 $31,678 - $80,934	-9,400 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $32,242 - $51,982	9,400 New	9,400 $32,000

257

173M

397K

444K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.57B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.